8-K 1 nby20201118_8k.htm FORM 8-K nby20201118_8k.htm








Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934


Date of earliest event reported: November 17, 2020


NovaBay Pharmaceuticals, Inc.

(Exact Name of Registrant as Specified in Charter)





(State or Other Jurisdiction

of Incorporation)

(Commission File Number)

(I.R.S. Employer

Identification No.)


2000 Powell Street, Suite 1150, Emeryville, CA     94608

(Address of Principal Executive Offices) (Zip Code)


(510) 899-8800

(Registrant’s telephone number, including area code)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))



Securities registered pursuant to Section 12(b) of the Act:


Title of Each Class


Trading Symbol(s)


Name of Each Exchange On Which Registered

Common Stock, par value $0.01 per share




NYSE American


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company □


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. □




Item 1.01     Entry into a Material Definitive Agreement


In connection with the previously disclosed launch by NovaBay Pharmaceuticals, Inc. (the “Company”) of CelleRx Clinical Reset, on November 17, 2020, the Company entered into a Consulting Agreement (the “Agreement) with Mr. Eric Wu. Pursuant to the Agreement, Mr. Wu will act as a consultant to the Company in support of the CelleRx product re-launch as well as in potential financings and other transaction opportunities. The term of the Agreement is for twelve (12) months.


As consideration for such services, the Company will grant Mr. Wu options exercisable for 300,000 shares of the Company’s common stock under the Company’s 2017 Omnibus Incentive Plan with an exercise price equal to the Company’s closing stock price on the date of the grant and vesting on the one year anniversary of the grant date. Mr. Wu is the Partner and Senior Vice President of China Kington Asset Management Co. Ltd., a company that has partnered with the Company in several transactions over the years as disclosed in the Company’s filings with the Securities and Exchange Commission, and the brother of Mr. Mijia (Bob) Wu, who serves on the Company’s Board of Directors.


The Agreement is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference. The above description of the terms of the Agreement are qualified in their entirety by reference to such exhibit.


Item 9.01.     Financial Statements and Exhibits.


(d)          Exhibits.



Exhibit No.





Consulting Agreement between the Company and Eric Wu, dated November 17, 2020






Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.



NovaBay Pharmaceuticals, Inc.



/s/ Justin M. Hall


    Justin M. Hall


    Chief Executive Officer and General Counsel



Dated: November 18, 2020